Furthermore, the AGAP2-AS1 gene knockdown was associated with restored sensitivity to treatment with trastuzumab in breast cancer cell lines previously overexpressing AGAP2-AS1 and resistant to this therapy [133]. The gene discussed is AGAP2; the disease is breast cancer.